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ABSTRACT 
In a recent study, whole-genome sequencing (WGS) of 17 families with incidence of non-
medullary thyroid carcinoma led to the identification of 41 significant germline variants in 40 
genes including 24 missense, five frameshift, five splice change, and seven nonsense variants. One 
variant, located within the Acylglycerol Kinase (AGK) gene, is both a frameshift and splice region 
variant (AGK c.521_522del). AGK encodes a mitochondrial membrane protein involved in lipid 
and glycerolipid metabolism by functioning as a lipid kinase to catalyze the phosphorylation of 
both monoacylglycerol and diacylglycerol to form lysophosphatidic acid (LPA) and phosphatidic 
acid (PA) respectively. Aside from functioning as a lipid kinase, AGK is a component of the 
TIM22 complex, which mediates the import and insertion of proteins into the mitochondrial inner 
membrane. Our study provides further characterization of the recently identified and validated 
frameshift variant, AGK c.521_522del, in the development of PTC. Our genetic and molecular 
data suggest altered expression of the encoded truncated protein results in loss-of-function, rather 
than a dominant negative function. However, as this is only one of many genes implicated in 
thyroid cancer, and its role has yet to be definitively characterized, future studies to refine the 
functionality of this gene as well as the additional risk of other loci will confer a better 
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INTRODUCTION  
Thyroid Carcinoma, a group of cancers that begin in the cells of the thyroid gland, is 
considered the most common malignancy of the endocrine system.1 The thyroid is a bilobed gland 
that sits in the neck just beneath the windpipe. The thyroid gland produces hormones that function 
in the maintenance of homeostasis and thus are crucial in controlling many regulatory processes 
including heartrate, blood pressure, temperature, and metabolism. The thyroid gland also 
contributes to the maintenance of blood calcium levels, thus contributing to the functioning of 
nerves and muscles.2 According to the National Cancer Institute, the number of new cases of 
thyroid cancer in 2019 was approximately 52,070, accounting for 3% of all new cancer cases.3 
Furthermore, in using statistical models for analysis, it was found the rate of new thyroid cancer 
cases has been rising about 1.9% each year over the last decade while death rates have also been 
rising around 0.7% each year.4 With respect to the United States specifically, the rate of new cases 
has been rising since the 1990s, making thyroid cancer among the fastest growing cancers today.5 
According to the American Cancer Society, thyroid cancer as well as most other thyroid disease, 
such as Hashimoto’s thyroiditis, are seen occurring three times more often in women than men, 
though the underlying factors predisposing to such are unknown at this time.6 Furthermore, while 
both development and onset of thyroid cancer can occur at any age, in the U.S. such risk has been 
observed to peak earlier for women than men.7 According to the American Cancer Society, risk 
factors for the development of thyroid cancer include gender, age, exposure to radiation, iodine 
levels in the diet, and family history.  
 As aforementioned, thyroid cancer is actually a group of cancers that begin in the cells of 
the thyroid. There are four main types of thyroid cancer: papillary thyroid carcinoma (PTC), 
follicular thyroid carcinoma (FTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid 
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carcinoma (ATC).8 Differentiating between these four types depends primarily upon how the 
cancer cells appear under the microscope.9 Medullary thyroid carcinoma (MTC) occurs in the C 
cells of the thyroid gland, which function in producing calcitonin, a hormone that when released 
reduces blood calcium levels.10 Non-medullary thyroid cancer, NMTC, (PTC, FTC, ATC), derived 
from the follicular cells of the thyroid gland, accounts for more than 90% of all thyroid cancers.11 
Both MTC and NMTC can occur in sporadic and familial forms. Hereditary MTC accounts for 20-
25% of all MTC and can either present associated with multiple neoplasia (MEN) IIA or IIB, or 
as pure familial MTC (FMTC).12 The genetic predisposition for FMTC is well understood and 
genotype-phenotype correlations are well-defined.13 However, the hereditary nature of and genetic 
predisposition to NMTC is not well established as it has only begun to emerge over the last 10 to 
20 years.14 
 Although NMTC is primarily sporadic, familial aggregation does occur.15 Based on both 
clinical and pathological findings, hereditary NMTC can be classified either as syndromic-
associated or pure familial NMTC (FNMTC).16 Regarding syndrome-related incidence, hereditary 
NMTC has been found to be associated with Cowden’s Syndrome (CS), Familial Adenomatous 
Polyposis (FAP), Carney’s Complex, and Werner’s Syndrome.17 Pure familial non-medullary 
thyroid cancer (FNMTC), defined as two or more affected family members, typically follows an 
autosomal dominant pattern of inheritance and represents 5-15% of NMTC and 3-9% of all thyroid 
cancers.18 Furthermore, FNMTC is thought to cause more aggressive disease.19 PTC, the most 
common histological subtype of FNMTC, often presents by itself within families and thus is 
termed familial PTC (FPTC).20 Other forms of FNMTC include PTC follicular variant, FTC, and 
rarely ATC.21  
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 Although the specific underlying genetic influence on FNMTC is not well established, 
case-control studies have shown that the development of both PTC and FTC is largely subject to 
hereditary factors (predisposing genes).22 In studies from Utah and Sweden, first degree relatives 
of probands, had an 8- and 12-fold risk respectively, to develop PTC/FTC, a degree of heritability 
among the highest of all cancers.23 One emerging factor known to influence genetic predisposition 
to PTC is the penetrance of a disease-causing variant. Of the variant genes known to strongly 
predispose to PTC, none account for more than a few cases.24 Such genes are termed highly 
penetrant. In contrast, variant genes displaying weaker or incomplete predisposition, termed low-
penetrant genes, may be more common.25 The high heritability of PTC is likely due to a collective 
contribution of genes that display both high and low penetrance.26  
Highly-penetrant genes are classically identified with methods of linkage analysis in 
affected families. This method aims to detect the chromosomal location of disease-causing variants 
based on the concept that genes residing close to one another on a chromosome remain linked 
during meiosis (unlikely to be separated onto distinct chromatids during recombination) and thus 
are more likely to be inherited together. A few loci found using this method of linkage analysis 
have been implicated in the genetic predisposition to thyroid cancer, including a linkage locus 
within chromosome 8q24 containing a maximum nonparametric linkage (NPL) score of 7.03.27 In 
this locus, a small 12 Kb haplotype, located within two known coding genes, thyroglobulin (TG) 
and Src-like adaptor (SLA), was found segregating with PTC.28 Within this region, a long 
noncoding RNA gene, AK023948, was found to be a candidate susceptibility gene for PTC. 
However, in the absence of obvious deleterious variants and because the molecular function of 
AK023948 itself has not been well-defined, no credibility regarding predisposition to PTC was 
assumed.29  
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In yet another study of a large family displaying NMTC (11 cases of PTC and 2 cases of 
ATC), linkage analysis revealed a locus in chromosome 4q32 yielding a maximum NPL score of 
18.5.30 Targeted deep sequencing of this region revealed a novel single nucleotide variant (SNV) 
in chromosome 4q32 (4q32 A>C) that was present in all affected family members and segregated 
with the disease phenotype in all but one affected individual.31 It was discovered that this highly-
penetrant 4q32 A>C variant was located in an enhancer element and both impaired this enhancer 
region’s ability to bind transcription factors and led to a downregulation in enhancer RNA (eRNA), 
further suggesting its implication in the predisposition to NMTC.32 In an additional study into the 
4q32 A>C variant, the Kaplan-Meier method of segregation was used to determine that individuals 
with such variant have a 68.9% risk to develop thyroid cancer by age 70.33 Interestingly, this 
variant was not found in 38 additional NMTC families, nor was it found in 2500 sporadic PTC 
cases and 2500 controls, suggesting this highly-penetrant variant is ultra-rare.34  
In another study, linkage analysis in a series of 38 PTC families followed by association 
studies revealed a candidate susceptibility gene in PTC, the Slit-Robo Rho GTPase activating 
protein 1 (SRGAP1) gene, within a locus on chromosome 12q14, displaying a PPL score of 30% 
that coincided with an NPL score of 2.8.35 Sequencing of all exons and exon-intron boundaries of 
SRGAP1 in one affected individual from each family compatible with linkage to 12q14 led to the 
discovery of five missense variants. Two such variants, each present within a single family, were 
identified as benign.36 The three potential disease-causing missense variants were found to co-
segregate with the PTC phenotype in their relevant families.37 Further analysis into these three 
missense variants’ function, or lack thereof, were highly suggestive of having deleterious effects. 
However, population data indicated low penetrance and thus the role of SRGAP1 variants in the 
overall predisposition to thyroid cancer are likely minute.38  
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Because all aforementioned highly-penetrant variants displaying a strong predisposition to 
PTC are quite rare, linkage analysis methods may not be as useful.39 Today, Next Generation 
Sequencing (NGS), which includes whole genome and whole exome sequencing methods, is used 
preferentially to detect high-penetrant variants predisposing to PTC.40 In a study of a PTC family 
with six affected individuals, whole genome sequencing (WGS) followed by whole exome 
sequencing (WES) and haplotype analysis revealed a heterozygous germline missense variant in 
the serine/arginine repetitive matrix 2 (SRRM2) gene (S346P) that co-segregated with PTC.41 
Functional analysis permitted the speculation that the mutant protein affects splicing of at least 
one of the genes specifically expressed in the thyroid, further implicating this rare, but highly-
penetrant variant in PTC predisposition.42  
In a recent study, WGS of 17 families with incidence of NMTC led to the identification of 
41 significant germline variants in 40 genes including 24 missense, five frameshift, five splice 
change, and seven nonsense variants.43 Sanger sequencing was used to validate all 41 highly-
penetrant variants and prove their co-segregation with NMTC.44 Of such identified variants, one, 
located within the Acylglycerol Kinase (AGK) gene (AGK c.521_522del), is both a frameshift and 
splice region variant. In this study, the role of AGK in the etiology of PTC has been characterized 
further.  
This frameshift and splice region variant in AGK was discovered in one large NMTC 
family. Within this family are four individuals affected with NMTC in at least three generations, 
including three cases of PTC and one case of ATC. AGK is located on the long arm of chromosome 
7 at position 34 (7q34). The identified variant occurs in exon 9, and results in a frameshift mutation 
in the encoded protein’s histidine residue AGK p.(His174fs). According to the US National 
Library of Medicine, AGK encodes a mitochondrial membrane protein involved in lipid and 
A Frameshift Variant in AGK in the Etiology of PTC  
 
Isabella V. Hendrickson 9 
glycerolipid metabolism by functioning as a lipid kinase to catalyze the phosphorylation of both 
monoacylglycerol and diacylglycerol to form lysophosphatidic acid (LPA) and phosphatidic acid 
(PA) respectively.45 This encoded protein consists of 422 amino acids and has a molecular mass 
of about 47 kD.46 Aside from functioning as a lipid kinase, AGK is a component of the TIM22 
complex, which mediates the import and insertion of proteins into the mitochondrial inner 
membrane.  
It has been observed that overexpression of AGK leads to increased proliferation in breast 
and prostate cancer through the suppression of FOXO1 (X. Wang et al., 2014) or activation of 
MAPK pathway (Berktas et al., 2015), respectively.47,48 Furthermore, AGK somatic mutations 
have been discovered in several cancers, most prominently uterine cancer.49 Defects in this gene 
have also been associated with mitochondrial DNA depletion syndrome 10.50 According to the 
GTEx Database, in looking at tissue specific expression of AGK, there is ubiquitous expression in 
the thyroid (RPKM 4.79, TPM 20.88) and 26 other tissues.51 The current hypothesis is that the 
frameshift and splice region variant in AGK results in gene expression changes and/or a dominant 
negative function that alters the metabolism of thyroid cells in the development of FNMTC.  
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METHODS 
Cell Lines: Cells of a PTC-derived cell line, TPC1, were incubated in Dulbecco’s Modified Eagle 
Medium (DMEM) with 10% fetal bovine serum (FBS) (Thermo Fisher), 1 X antibiotic-
antimycotic (Thermo Fisher), and 1 X Plasmocin prophylactic (InvivoGen) at 37˚C in humidified 
air with 5% CO2. This cell line was obtained from Rebecca Schweppe (University of Colorado 
Cancer Center, Denver, CO).  
 
PCR: PCR of wild type and variant AGK was performed using AmpliTaq Gold (Thermo Fisher) 
under standard PCR conditions.  
 
Generation of Plasmid Constructs: The coding sequence of wild-type AGK (position 40-1308) 
was PCR amplified using AccuPrime Taq (Thermo Fisher). The product was then purified and 
cloned into XhoI and HindIII sites of the pCMV6-Entry Tagged Cloning Vector. All cloning was 
performed using T4 DNA Ligase (New England BioLabs). The frameshift variant was induced 
using the GeneArt Site-Directed Mutagenesis PLUS System (Thermo Fisher).  
 
Transient Transfection: TPC1 cells incubating in Dulbecco’s Modified Eagle Medium (DMEM) 
with 10% fetal bovine serum (FBS) (Thermo Fisher) were transiently transfected with 10 µg of 
either pCMV6-Empty, AGK wild-type, or AGK mutant plasmid DNA using Lipofectamine 2000 
(Thermo Fisher) and Opti-MEM I Reduced Serum Medium. The cells were given fresh DMEM 
with 10% FBS after 4 hours and then harvested after 24 hours.  
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Western Blotting: 24 hours after transient transfection, TPC1 cells were lysed in 1 X RIPA Lysis 
and Extraction Buffer (Thermo Fisher) with 1 X Halt protease/phosphatase inhibitor (Thermo 
Fisher). Equal amounts of protein were boiled and eluted in 1 X Laemmli buffer (Bio-Rad) 
containing 2-mercaptoethanol (Sigma-Aldrich). Proteins were then loaded onto a 4-20% TGX 
Stain-Free precast SDS-PAGE gel with All Blue Protein Standards (Bio-Rad). Gels ran at 100 V 
for 10 minutes, then 150 V for 60 minutes. Gels were activated under UV light using a ChemiDoc 
(Bio-Rad). Total protein was visualized under UV light using a ChemiDoc (Bio-Rad). Following 
total protein visualization, gels were transferred to low-fluorescence polyvinylidene fluoride 
membranes using an RTA transfer kit (Bio-Rad) and Trans-Blot Turbo system (Bio-Rad). Total 
protein was visualized on the blot under UV light using a ChemiDoc (Bio-Rad). Blots were then 
blocked in 5% non-fat milk in tris-buffered saline with Tween 20 (TBS-T) at room temperature 
for 1 hour. Following blocking, blots were probed with unconjugated monoclonal primary 
antibody in 5% non-fat milk (FLAG [M2] Sigma, GAPDH-HRP [0411] Santa Cruz) at 4˚C 
overnight. Blots were then washed in TBS-T and incubated in conjugated polyclonal secondary 
antibody at room temperature for 1 hour (anti-mIgG-HRP Sigma or anti-rIgG-HRP Cell 
Signaling). Blots were washed in TBS-T and Clarity Enhanced Chemiluminescence (ECL) (Bio-
Rad) was performed. Chemiluminescence was visualized using a ChemiDoc (Bio-Rad) and 
through exposure of Blue Basic Autorad Double Emulsion Film (GeneMate). To re-probe, blots 
were first washed in TBS-T, then quenched in 15% H2O2 in phosphate-buffered saline (PBS) 
(Thermo Fisher) at room temperature for 15 minutes.   
 
Microscopy: Coverslips were exposed to UV light for 15 minutes on each side then treated with 
poly-D-lysine (0.1 mg/ml) for 5 minutes at room temperature. Coverslips were then washed with 
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PBS and dried for 2 hours. For observation of endogenous AGK expression, 250,000 TPC1 cells 
were seeded on these pretreated coverslips. After 24 hours, cells were washed in PBS, fixed in 4% 
paraformaldehyde for 5 minutes, and permeabilized in 0.25% Triton X-100 for 15 minutes. After 
washing with PBS, the cells were blocked in 10% donkey serum in a humidified chamber at 4˚C 
overnight. Cells were then incubated with unconjugated primary antibodies (AGK (HPA020959 
Atlas, alpha tubulin (DM1A) Abcam) in 5% donkey serum in a humidified chamber at 4˚C 
overnight. After washing with PBS supplemented with 0.1% of 10% Tween (PBS-T), cells were 
incubated in conjugated secondary antibody (anti-mIgG Alexa Fluor 647 Thermo Fisher or anti-
rIgG Alexa Fluor 488 Thermo Fisher) in 5% donkey serum at room temperature for 1 hour in the 
dark. After washing with PBS-T, coverslips were mounted on microscope slides with 1 drop of 
Diamond ProLong Antifade with 4’,6-diamidino-2-phenylindole (Thermo Fisher) and cured 
overnight in the dark at room temperature. For observation of exogenous wild-type and truncated 
AGK expression, 250,000 TPC1 cells were seeded on pretreated coverslips. After 24 hours, 
250,000 TPC1 cells, transiently transfected over 24 hours with either pCMV6-Empty, AGK wild-
type, AGK mutant plasmid DNA, were seeded on these pretreated coverslips. After 24 hours, cells 
were either stained with 100 mM MitoTracker Red CMXRos (Thermo Fisher) in DMSO for 15 
minutes, or left unstained. All cells were then washed in PBS, fixed in 4% paraformaldehyde for 
5 minutes, and permeabilized in 0.25% Triton X-100 for 15 minutes. After washing with PBS, the 
cells were blocked in 10% donkey serum in a humidified chamber at 4˚C overnight. Cells were 
then incubated with unconjugated primary antibodies (alpha tubulin [DM1A] Abcam, or FLAG 
[M2] Sigma) in 5% donkey serum in a humidified chamber at 4˚C overnight. After washing with 
PBS supplemented with 0.1% of 10% Tween (PBS-T), cells were incubated in conjugated 
secondary antibody (anti-mIgG Alexa Fluor 647 Thermo Fisher or anti-rIgG Alexa Fluor 488 
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Thermo Fisher) in 5% donkey serum at room temperature for 1 hour in the dark. After washing 
with PBS-T, coverslips were mounted on microscope slides with 1 drop of Diamond ProLong 
Antifade with 4’,6-diamidino-2-phenylindole (Thermo Fisher) and cured overnight in the dark at 
room temperature. Cells were visualized and imaged using a FV3000 confocal laser scanning 
microscope (Olympus).  
 
Proliferation Assay: Equal amounts of the tetrazolium salt, WST-8 ([2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophneyl)-2H-tetrazolium, monosodium salt)]), were 
added to TPC1 cells seeded in a 24-well plate and transiently transfected over 24 hours with 
reported plasmids as described above. Proliferation was measured according to the extracellular 
reduction of WST-8, which results in an orange colored dye, formazan. The amount of formazan 
produced, measured as the absorption at 450 nm by a SpectraMax M2e Multilabel Microplate 
Reader (Marshall Scientific), is directly proportional to the number of viable cells.  
 
Flow Cytometry: Following transient transfection, TPC1 cells were washed twice with PBS and 
then resuspended in PBS. Cell suspensions were passed through a 100 µm cell strainer into 
polystyrene tubes and stained with propidium iodide. Cell suspensions were then incubated on a 
shaker in the dark for 15 minutes and analyzed on a LSR II flow cytometer (BD Biosciences).  
 
Statistical Analysis: All graphical data are represented by mean±SEM. All p values reported are 
calculated from a two-sided t-test.  
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RESULTS 
AGK c.521_522del shows co-segregation with PTC in one large NMTC family.  
In a previous study, whole genome sequencing (WGS) of 17 families with incidence of non-
medullary thyroid cancer (NMTC) led to the identification of 41 significant germline variants.52 
Sanger sequencing validated all 41 variants, and proved their co-segregation with NMTC. 5 of 
these 41 variants were found to co-segregate with PTC in one of these 17 families. All but one of 
such identified variants are either missense or nonsense variants resulting from single nucleotide 
substitutions (Table 1). The other variant, located within exon 9 of the Acyglycerol Kinase 
(AGK) gene, is a both a frameshift and splice region variant (AGK c.521_522del). Like the other 
4 variants, AGK c.521_522del displays co-segregation with all three PTC cases in this single 
NMTC family, as well as one ATC case (Figure 1). This variant was also identified in a family 
member that had a thyroidectomy due to prior presence of a benign thyroid disease. This variant 
was not found in any unaffected family member available for sequencing or linkage analysis 
(Figure 1). In addition to its co-segregation with PTC and the detrimental nature of frameshift 
variants, this variant posed as an interesting candidate to characterize further due to the 
ubiquitous expression of AGK in thyroid tissue (RPKM 4.79, TPM 20.88).53 
 
Sanger sequencing and Western blotting analysis validate a truncated protein.  
In the previous study, Sanger sequencing was performed to validate the incidence of all identified 
41 variants, as well as their co-segregation with PTC in each respective NMTC family. Sanger 
sequencing of AGK variant carriers confirmed the presence of a frameshift variant (Figure 2A). 
This frameshift variant, AGK c.521_522del, located in exon 9 in AGK, and within a histidine 
residue of the encoded protein AGK p.(His174fs), results in the protein truncating after a tyrosine 
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residue (Figure 2B). We generated this truncated protein in an expression plasmid and transiently 
transfected a PTC-derived cell line, TPC1, with the truncated plasmid DNA. Western blotting was 
performed with proteins harvested from the transiently transfected cells in order to confirm the 
identity of the truncated protein as compared to the wild-type (Figure 2C). The wild-type AGK 
protein plus the FLAG tag consisted of 432 amino acids was expected to have a molecular weight 
of around 48.34 KDa.54 The truncated AGK protein, AGK p.(His174fs), plus the FLAG tag 
consisted of 184 amino acids and was expected to have a molecular weight of around 20.31 KDa. 
These predicted values were observed in the Western blot. The tagged wild-type and truncated 
AGK proteins were observed on the blot around 50 KDa and between 20 and 25 KDa, respectively 
(Figure 2C). Also observed through Western blotting analysis was a discrepancy between the 
expression levels of the wild-type and truncated AGK proteins. The wild-type protein appears to 
have a much higher level of expression than the truncated protein (Figure 2C).  
 
Overexpression of AGK and proliferation.   
In order to determine if overexpression of the variant form of AGK (AGK c.521_522del) led to 
increased proliferation, we performed colorimetric assays using TPC1 cells transiently transfected 
with either AGK wild-type, AGK c.521_522del, or empty pCMV6 plasmid DNA over 24 hours. 
Proliferation was measured through the extracellular reduction of WST-8, which was added in 
equal amounts to the cells. The reduction of WST-8 produces an orange colored dye, formazan. 
450 nm absorption of formazan indicated the number of viable cells. We found that overexpression 
of the truncated form of AGK resulted in decreased proliferation of TPC1 cells relative to the 
empty pCMV6 vector (Figure 3A). Through conducting cell cycle analysis using flow cytometry, 
we determined overexpression of the truncated form of AGK did not result in a significantly higher 
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percentage of TPC1 cells existing in both S and G2/M phases relative to either the empty pCMV6 
vector or wild-type form (Figure 3B). These results suggest the AGK truncated protein does not 
gain a dominant negative function leading to an alteration in metabolic activity of thyroid cells in 
the development of FNMTC. 
 
Localization of both wild-type and variant AGK.  
According to the Human Protein Atlas, in studies using HEK 293, U-2 OS, and U-251 MG cell 
lines, AGK mainly localized to the mitochondria.55 Before attempting to visualize how the 
truncated protein localizes in the cell with respect to the mitochondria, we conducted 
immunofluorescence staining to visualize AGK’s endogenous expression in the thyroid cancer-
derived cell line, TPC1. We discovered the protein has a more pan distribution than what was 
expected, given the previous studies conducted with other cell lines (Figure 4). In looking at the 
DAPI and alpha-tubulin staining, AGK was not restricted to either nuclear or cytoplasmic cellular 
compartment, again revealing a more pan distribution (Figure 4). In order to characterize if the 
potential role of loss-of-function in the etiology of PTC manifests itself in altered expression 
within or surrounding the mitochondria, we performed immunofluorescence staining on TPC1 
cells transiently transfected with either AGK wild-type, AGK c.521_522del, or empty pCMV6 
plasmid DNA over 24 hours. Due to non-specific binding of the anti-FLAG antibody, evident in 
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DISCUSSION AND FUTURE DIRECTIONS 
In a previous study, Sanger sequencing was performed to validate that a frameshift variant 
in the acylglycerol kinase (AGK) gene, identified by WGS, co-segregating with PTC in a single 
FNMTC family.56 This frameshift variant, AGK c.521_522del, occurs in a histidine residue [AGK 
p.(His174fs)] resulting in the protein truncating after a tyrosine residue. In the present study, we 
have attempted to further characterize the role of AGK c.521_522del in the etiology of PTC. As 
mentioned previously, AGK encodes a lipid kinase located within the inner mitochondrial 
membrane that functions in both lipid and glycerolipid metabolism. The AGK frameshift variant, 
AGK c.521_522del, is located within the region that encodes this protein’s diacylglycerol kinase 
catalytic (DAGKc) domain. This conserved DAGKc domain mediates AGK’s kinase activity in 
lipid metabolism through binding ATP and phosphorylating target molecules, suggesting any 
consequential changes in gene expression could alter the metabolism of thyroid cells in the 
development of FPTC.57  
Through Western blotting analysis, we showed there was differential expression of the 
wild-type and truncated AGK proteins. The wild-type AGK protein displayed a higher level of 
expression than the truncated AGK protein, suggesting a potential discrepancy in relative stability 
between the two. Since the mutant protein truncates after a tyrosine residue, and thus only contains 
175 of the 422 amino acids present in the wild-type AGK protein, it is possible that a loss in 
secondary and/or tertiary structure is responsible for this instability. This putative instability of the 
truncated AGK protein could also be due in part to an inability to associate with other molecules, 
such as those that mediate its association with the inner mitochondrial membrane, which could be 
assessed through co-immunoprecipitation. In order to definitively characterize the differential gene 
expression profiles between AGK c.521_522del and the wild-type, quantitative PCR should be 
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performed. Regardless, these findings allowed us to hypothesize that this frameshift in AGK 
resulting in gene expression changes could lead to a loss-of-function or a dominant negative 
function that alters the metabolism of thyroid cells in the development of familial PTC.  
In other studies, it has been found that overexpression of AGK leads to increased 
proliferation and tumorigenicity in breast and prostate cancer through the suppression of the 
FOXO1 transcription factor (X. Wang et al., 2014), or cross talk with EGFR and thus activation 
of MAPK pathway (Berktas et al., 2015), respectively.58,59 In order to identify whether or not the 
truncated AGK protein gains a dominant negative function leading to tumorigenicity in the 
development of PTC, we performed proliferation assays. Surprisingly, we found that 
overexpression of the truncated AGK protein resulted in decreased proliferation of cells from a 
thyroid cancer-derived cell line (TPC1). Furthermore, through performing cell cycle analysis, we 
determined that overexpression of the truncated AGK protein did not result in a significantly 
higher percentage of TPC1 cells existing in both S and G2/M phases relative to either the empty 
pCMV6 vector or wild-type AGK protein. These results seem to suggest that, rather than gaining 
a dominant negative function leading to tumorigenicity in PTC, AGK c.521_522del has a 
protective function against the development of PTC. It is, however, possible that this 
overexpression system may not recapitulate what is happening on an endogenous level. For these 
studies, either patient lymphoblast cells or isogenic CRISPR-Cas9-engineered cell lines would 
need used to determine the phenotype of this variant. Furthermore, this frameshift variant in AGK 
resulting in altered gene expression could still lead to a loss-of-function relevant in the 
development of PTC.  
A potential loss-of-function in the AGK mutant protein could alter the integrity of the 
mitochondria. However, the truncated AGK protein likely still associates with the inner 
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mitochondrial membrane because it retains its N-terminal mitochondrial localization sequences. 
Defects in AGK resulting in loss-of-function have been identified as the causative agent 
responsible for the development of Mitochondrial DNA Depletion Syndrome 10 (MTDPS10). 
MTDPS10, commonly known as Senger’s Syndrome, is an autosomal recessive mitochondrial 
disorder characterized by the presence of many conditions including cataracts, cardiomyopathy, 
and skeletal myopathy.60 AGK’s role in the development of MTDPS10 has been characterized as 
two-fold in accordance with the encoded protein’s two completely independent functions. First, 
AGK’s functionality as a lipid kinase, and thus its catalytic activity, was found to play a central 
role in maintaining the structural integrity of the mitochondrial cristae.61 Because mitochondria 
are known to trigger apoptotic cell death through cristae remodeling and fragmentation, AGK’s 
enzymatic functionality becomes vital in a cell’s apoptotic resistance. Mutations in AGK leading 
to loss-of-function of the encoded protein have been noted as the causative factor responsible for 
abnormal cristae morphology identified in MTDPS10 patients’ cells.62 Independent of its catalytic 
activity, AGK’s role as a component of the TIM22 complex has also been identified in the etiology 
of MTDPS10. Functional AGK associated with TIM22 and TIM29 to form the TIM22 complex, 
which mediates both the transport and integration of multi-pass transmembrane proteins, such as 
the adenosine nucleotide translocator 1 (ANT1) protein, into the inner membrane of the 
mitochondria.63 Loss of AGK was found to impede the assembly of the TIM22 complex, which 
explains the decreased expression of ANT1 observed in  MTDPS10 cells.64 It is possible that one 
or both of such consequences involved in the development of MTDPS10 also arise in the 
tumorigenicity of PTC due to a loss-of-function of the truncated AGK protein.  
We performed immunofluorescence staining on the PTC-derived cell line, TPC1, to 
identify if perhaps a loss-of-function of the truncated AGK protein manifests in altered expression 
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within or surrounding the mitochondria. Given evidence of non-specific binding in our control 
samples, our results were inconclusive. In order to further characterize the potential consequences 
of a loss-of-function of the truncated AGK protein, studies into the complete loss-of-function, 
apoptosis, and TIM22 complex functionality should be performed. Knockdown of AGK 
expression in TPC1 cells using either siRNA or shRNA could be conducted to study the potential 
impact of loss-of-function. Global expression profiling could be conducted with patients’ cells to 
identify differential expression patterns between the wild-type and truncated AGK proteins upon 
being subjected to apoptotic stimuli. Western blotting could also be performed to identify 
differences between the wild-type and truncated AGK proteins in their expression of certain 
apoptotic markers, such as cytochrome c. In terms of TIM22 complex functionality, co-
immunoprecipitation analysis should be performed to identify if the truncated AGK protein is able 
to interact with both TIM22 and TIM29 in order to form the translocator complex. Furthermore, 
since ANT1 relies upon TIM22 for its insertion into the inner mitochondrial membrane, and 
because it is directly involved in metabolism through functioning as an ATP/ADP exchanger, its 
role in the development of PTC should also be considered.   
Overall, our study provides further characterization of the recently identified and validated 
frameshift variant, AGK c.521_522del, in the development of PTC. Our genetic and molecular 
data suggest altered expression of the encoded truncated protein results in loss-of-function, rather 
than a dominant negative function. However, as this is only one of many genes implicated in 
thyroid cancer, and its role has yet to be definitively characterized, future studies to refine the 
functionality of this gene as well as the additional risk of other loci will confer a better 
understanding of genes predisposing to thyroid carcinoma.   
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Table 1: AGK c.521_522del is One of the 5 Variants Identified in One NMTC Family.  
In a previous study of 17 families with incidence of non-medullary thyroid cancer (NMTC), whole 
genome sequencing (WGS) identified 41 germline variants in 40 candidate genes predisposing to 
thyroid cancer. Shown here are 5 of such identified variants, which were discovered within a single 
family. The reference nucleotide(s) denotes the wild-type genotype at the given position, whereas 
the alternate represents the variant. Within the family, all individuals with PTC (affected) are 
carriers of all five variants. Family members available for analysis and unaffected by PTC do not 
carry any of the identified variants. Therefore, these 5 variants display co-segregation with PTC 
in this single NMTC family.65    
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Figure 1: Pedigree of the NMTC family in Which AGK c.521_522del Displays Co-Segregation 
with PTC.  
Pedigree of the non-medullary thyroid cancer (NMTC) family in which AGK c.521_522del 
cosegregates with all three cases of PTC. Family structure is indicated by the pedigree map. 
Squares represent males, and circles represent females. Generations are labeled using Roman 
numerals. Individuals are represented by both their generation and order in which they appear. 
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Figure 2: The Frameshift Mutation, AGK c.521_522del, Occurs in a Histidine Residue, [AGK 
p.(His174fs).] Resulting in the Encoded Protein Truncating After a Tyrosine Residue.   
(A) Sanger sequencing data used in a previous study to identify AGK as one of 41 rare high 
penetrant variants predisposing to PTC. Sequencing data from individual II.3, unaffected by PTC 
nor AGK c.521_522del, is compared to sequencing data from individual III.2, affected by PTC and 
AGK c.521_522del. (B) Linear schematic of the wild-type and truncated AGK protein forms. 
Functional groups and the frameshift variant are labeled. The hydrophobic region is labeled in 
orange and the diacylglycerol kinase catalytic (DAGKc) domain is labeled in green. (C) 
Representative Western blot of cells transfected with AGK constructs, AGK wild-type (WT), AGK 
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Figure 3: Proliferation Assays and Cell Cycle Analysis.  
WST-8 absorption and flow cytometry identify differential proliferation of TPC1 cells 
transiently transfected with plasmid DNA over 24 hours. (A) Proliferation was measured as the 
absorption of formazan at 450 nm, which is directly proportional to the number of viable cells. 
Quantitation of the absorption was normalized according to the empty pCMV6 vector. Results 
are shown as mean±SEM, n=3. *p<0.05 (two-tailed t test). (B) The percentage of TPC1 cells 
transiently transfected with plasmid DNA at each stage of the cell cycle. Results are shown as 
mean±SEM, n=3. Flow cytometry histograms from TPC1 cells transiently transfected with either 
the (C) pCMV6 empty vector (pCMV6), (D) AGK wild-type (AGK WT), or (E) AGK 
c.521_522del (AGK TRUNC) for 24 hours. Cells were stained with propidium iodide. The 
percentage of cells at each stage of the cell cycle were obtained from these histograms.   
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Figure 4: Confocal Image of Endogenous AGK Expression in TPC1 Cells.  
Endogenous expression of the AGK protein in a PTC-derived cell line, TPC1. 
Immunofluorescence staining was performed in order to visualize this expression under a confocal 
microscope. All images were taken under 60 X magnification. The scale bar, denoted in white, 
represents a distance of 10 um.  
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